<Record><identifier xmlns="http://purl.org/dc/elements/1.1/">URN:NBN:SI:DOC-Y9QQ7E3P</identifier><date>2022</date><creator>Čemažar, Maja</creator><creator>Serša, Gregor</creator><relation>documents/doc/Y/URN_NBN_SI_doc-Y9QQ7E3P_001.pdf</relation><relation>documents/doc/Y/URN_NBN_SI_doc-Y9QQ7E3P_001.txt</relation><format format_type="type">article</format><format format_type="extent">Str. 107-110</format><identifier identifier_type="COBISSID_HOST">102347523</identifier><identifier identifier_type="URN">URN:NBN:SI:doc-Y9QQ7E3P</identifier><language>slv</language><publisher publisher_location="Ljubljana">Katedra za onkologijo</publisher><publisher publisher_location="Ljubljana">Onkološki inštitut</publisher><publisher publisher_location="Ljubljana">Sekcija za internistično onkologijo</publisher><source>Melanom in nemelanomski kožni raki</source><rights>InC</rights><subject language_type_id="slv">elektrokemoterapija</subject><subject language_type_id="slv">melanom</subject><subject language_type_id="slv">rak kože</subject><title>Elektronski vir</title><title>Gene immunotherapy of basal cell carcinoma: phase I clinical trial</title><title>Genska imunoterapija pri bazalno celičnem karcinomu: klinična študija faze I</title></Record>